A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease
for Heterozygous Familial Hypercholesterolemia
8 locations incl. Dothan
Sponsor: Verve Therapeutics, Inc.
Sex: All·Age: 18 - 70
Code: NCT06164730·Phase 1·Recruiting·Listed Dec 2023